DYN vs MDGL
DYN: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform. MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Side-by-side fundamentals
| Metric | DYN | MDGL | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $25.18 | $551.25 | |
| Market cap as of 2026-08-03 | $4.7B | $12.7B | |
| PEG as of 2026-08-03 | n/a | -134.35 | |
| Net margin as of 2026-08-03 | n/a | -27.3% | |
| Gross margin as of 2026-08-03 | n/a | +93.1% | |
| Operating margin as of 2026-08-03 | n/a | -27.9% | |
| ROE as of 2026-08-03 | -58.3% | -50.1% | MDGL higher |
| ROA as of 2026-08-03 | -46.8% | -25.4% | MDGL higher |
| Debt / equity as of 2026-08-03 | 0.18 | 0.63 | DYN lower |
| Revenue growth (YoY) as of 2026-08-03 | n/a | +256.8% | |
| Beta as of 2026-08-03 | 1.79 | -1.05 | |
| 1-year return as of 2026-07-31 close | +155.6% | +84.7% | DYN higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.